Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dolutegravir Sodium,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
ACTG Launches Tuberculosis Drug Interaction Trial Among HIV Patients
Details : Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for HIV-associated tuberculosis.
Product Name : Tivicay
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : Dolutegravir Sodium,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable